1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for 'CFS'.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 11th November 2024 is here.
    Dismiss Notice
  3. Welcome! Read the Core Purpose and Values of our forum.
    Dismiss Notice

Review A systematic review and meta-analysis of urinary biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), 2023, Taccori et al

Discussion in 'ME/CFS research' started by Andy, Jul 6, 2023.

Tags:
  1. Andy

    Andy Committee Member

    Messages:
    23,041
    Location:
    Hampshire, UK
    Background

    Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a multifactorial illness that affects many body systems including the immune, nervous, endocrine, cardiovascular, and urinary systems. There is currently no universal diagnostic marker or targeted treatment for ME/CFS. Urine is a non-invasive sample that provides biomarkers that may have the potential to be used in a diagnostic capacity for ME/CFS. While there are several studies investigating urine-based biomarkers for ME/CFS, there are no published systematic reviews to summarise existing evidence of these markers. The aim of this systematic review was to compile and appraise literature on urinary-based biomarkers in ME/CFS patients compared with healthy controls.

    Methods
    Three databases: Embase, PubMed, and Scopus were searched for articles pertaining to urinary biomarkers for ME/CFS compared with healthy controls published between December 1994 to December 2022. The final articles included in this review were determined through application of specific inclusion and exclusion criteria. Quality and bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Case Control Studies. A meta-analysis according to Cochrane guidelines was conducted on select studies, in particular, those that investigate urinary free cortisol levels in ME/CFS patients compared to healthy controls using the program STATA 17.

    Results
    Twenty-one studies were included in this review. All of the studies investigated urinary-based markers in ME/CFS patients compared with healthy controls. The reported changes in urinary outputs include urinary free cortisol (38.10%), carnitine (28.6%), iodine (4.76%), and the metabolome (42.86%). In most cases, there was minimal overlap in the main outcomes measured across the studies, however, differences in urinary free cortisol between ME/CFS patients and healthy controls were commonly reported. Seven studies investigating urinary free cortisol were included in the meta-analysis. While there were significant differences found in urinary free cortisol levels in ME/CFS patients, there was also substantial heterogeneity across the included studies that makes drawing conclusions difficult.

    Conclusions
    There is limited evidence suggesting a consistent and specific potential urinary-based biomarker for ME/CFS. Further investigations using more standardised methodologies and more stringent case criteria may be able to identify pathophysiological differences with diagnostic potential in ME/CFS patients compared with healthy controls.

    Open access, https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-023-04295-0
     
    Andy, Jul 6, 2023
    #1
    ahimsa, sebaaa, Sean and 7 others like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,384
    Location:
    Aotearoa New Zealand
    Looks like a solid study from what I have read so far. From NCNED

    21 studies on urine in ME/CFS were found.
    14 properly matched ME/CFS participants with controls.
    16 noted the ME/CFS criteria used.
    11 are reported as using appropriate statistical analysis


    8 studies investigated cortisol, with 4 finding reduced levels, 3 finding no significant difference and 1 reportedly not being clear what they found. The high number of studies on urinary cortisol relative to anything else reflects the fixation on HPA axis and stress responses as being the key to ME/CFS. I've commented elsewhere about the reasons we might expect to find slighter lower but still normal levels of cortisol in people with ME/CFS (delayed morning waking peak; reduced physical activity). So, there's nothing to see there. But still, people keep measuring cortisol, in blood, in saliva, in hair and in urine, expecting to find something game-changing.
    Researchers have looked at cortisol metabolites too:
    It sounds as though little attention has been paid to the presence or absence of PEM. The only comment about PEM in this paper was:
    I'm not sure if there is a typo in there, but nothing is reported about investigations of levels in urine during PEM. We really need to get samples taken when people are in florid PEM. The finding of the hypoxanthine is interesting given it is an ATP degradation product, with higher levels being observed in hypoxic clinical conditions, but it's hard to make a hypothesis when we don't know how the levels are changing with symptoms. 'Whether PEM was experienced in the seven days prior to urine collection' surely is nowhere near specific enough.

    There's more of note in this study.
     
    Hutan, Jul 6, 2023
    #2
    Lindberg, sebaaa, shak8 and 9 others like this.
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,384
    Location:
    Aotearoa New Zealand
    Nice to see this highlighting of the issues with Fukuda.
     
    Hutan, Jul 6, 2023
    #3
    shak8, Sean, Michelle and 4 others like this.
  4. Creekside

    Creekside Senior Member (Voting Rights)

    Messages:
    1,221
    Before, during and after. PEM is easy enough to plan in advance, so you can get a reliable baseline, then observe while it rises, then falls (hopefully back to the baseline). That might be more useful than comparing with "healthy controls".
     
    Creekside, Jul 6, 2023
    #4
    obeat, Sean, Hutan and 2 others like this.
  5. Hutan

    Hutan Moderator Staff Member

    Messages:
    29,384
    Location:
    Aotearoa New Zealand
    Somewhat easy, but can't be timetabled. It can be hard to know when florid PEM will strike and how long it will last for. I think you'd either have to have people come into a residential clinic for a few days to do triggering activities and then wait for the full-on PEM, or have systems for collection of samples at home. I believe Chris Armstrong is doing good day, bad day testing. I don't think we've heard much from him for a while.
     
    Hutan, Jul 6, 2023
    #5
    alktipping, RedFox, bobbler and 3 others like this.
  6. dreampop

    dreampop Senior Member (Voting Rights)

    Messages:
    444
    Unless I am mistaken they don't include the recent Hanson study in this review. That was a pre/post CPET study that found me/cfs patients changes were unexpectedly lower suggesting a blunted response to stressors . It may just have been too recent. They don't mention hypoxanthine outside of a discussion of female controls (it wasn't raised in any case).

    https://www.mdpi.com/1422-0067/24/4/3685

    It certainly seems worth of repeating a similar study. I do wonder if patients (perhaps NIH study did this) are only really providing results mid-day/morning and if night time, later afternoon and further CPET studies would be a of value.
     
    dreampop, Jul 7, 2023
    #6
    Trish, RedFox, Hutan and 3 others like this.
  7. Creekside

    Creekside Senior Member (Voting Rights)

    Messages:
    1,221
    I'm pretty sure my journal never used the term "florid PEM". My PEM was pretty consistent for known triggers, and I don't think it ever lasted more than a day, so in my experience, PEM was easy to plan in advance. I certainly couldn't plan for a major crash, since I never had one. Surely there are more people with consistent PEM triggers and responses.
     
    Creekside, Jul 7, 2023
    #7
    obeat likes this.

Share This Page